Were N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
| Registrars: |
Capita Registrars |
| CEO: |
Nigel Theobald |
| Executive Director: |
David Templeton, Luke Cairns |
| Non-Executive Chairman: |
Chris Britten |
| Address: |
6th Floor, 60 Gracechurch Street, London, United Kingdom |
| Phone: |
|
| Fax: |
|
| Website: |
http://www.n4pharma.com/ |
| Email: |
|